(Reuters) -Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a new chance to clear a path to launch cheaper generic versions of the medicine. The U.S. Court of Appeals for the Federal Circuit said that the last remaining J&J patent covering its Invega Sustenna may be invalid, sending the case back for a New Jersey federal court to reconsider. A J&J spokesperson said the company will "continue defending the intellectual property of Invega Sustenna."
The most common asthma inhaler for children was discontinued at the start of this year, forcing parents and pediatricians to scramble to switch to an alternative. But more than a month later, the situation has not improved, and families remain caught in the middle of a fight between a drug company and pharmacy benefit managers…
Pfizer has agreed to pay $93 million to settle antitrust claims by wholesale drug distributors that accused it of conspiring with India's Ranbaxy Laboratories to delay sales of less expensive, generic versions of the cholesterol drug Lipitor. Attorneys for Lipitor purchasers including Rochester Drug Co-Operative Inc and Puerto Rico's Drogueria Betances LLC disclosed the agreement in a filing on Wednesday in U.S. court in Trenton, New Jersey. The distributors' case will continue against Ranbaxy, the attorneys filing said.
Amid ongoing ADHD drug shortages, Adderall supplies have improved, but other brand name and generic medications such as Ritalin are still hard to come by, doctors say.
Do you know which things you should always buy generic instead of name brands? You might be surprised by some of these suggestions from money expert Dave Ramsey. I'm a Financial Expert: Always Buy the.